Jefferies keeps buy on GSK, sees 35% upside on promising B7H3 cancer drug program

Jefferies maintains a 'buy' rating and 2,500p target on GSK PLC, highlighting its B7H3 cancer drug program as a major undervalued opportunity. Encouraging data from small cell lung cancer studies and promising survival outcomes in China support this view. GSK is developing risvutatug rezetecan targeting B7H3 for lung, prostate, and colorectal cancers, with further trial results expected in 2027. The company also sees growth potential in respiratory treatments and hepatitis B therapies, while integrating AI into drug development processes.

GSK's cancer drug program news adds to investor interest as the stock trades at USD 50.07 on Pluang, showing a modest gain of 0.74% as of Sep 29, 2026 19:14 WIB. The company’s market cap stands at $98.58 billion, with a dividend yield of 3.66%, reflecting steady investor confidence in its health sector prospects.